LDLR and atherosclerosis: Accordingly, the morphometric analysis of atherosclerotic lesions at the aortic arch (Figure 6D) as well as the lipid content of the aortas and aortic arch (Figures 6E,F) of Ldlr−/− mice also showed that the scFv-anti-LDL(-)-MCMN-Zn nanoformulation was more effective to inhibit the atherosclerosis progression than the scFv-anti-LDL(-) non-derivatized on the surface of the nanoparticles.